Trademark Search in Canada

RUZURGI

View On IC.GC.CA

REGISTERED

on 17 May 2024

Last Applicant/ Owned by

MÉDUNIK CANADA INC.

950 Boul Michèle-BohecBlainville

QUEBEC

J7C5E2

Serial Number

1999215 filed on 4^th Dec 2019

Registration Number

TMA1233169 registered on 17^th May 2024

Registration expiry Date

17^th May 2034

Correspondent Address

FASKEN MARTINEAU DUMOULIN LLP

800 rue du Square Victoria, bureau 3500Montréal,

QUEBEC

H4Z1E9

RUZURGI

Trademark usage description

pharmaceutical preparations for the treatment of autoimmune, neurological, muscular, and neuromuscular diseases and disorders, namely lambert-eaton my Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of autoimmune, neurological, muscular, and neuromuscular diseases and disorders, namely Lambert-Eaton myasthenic syndrome (LEMS)

Classification kind code

Mark Details

Serial Number

1999215

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 26 on 31^st Jan 2024	Approved
Submitted for opposition 22 on 12^th Jun 2023	Search Recorded
Submitted for opposition 20 on 12^th Jun 2023	Examiner's First Report
Submitted for opposition 287 on 6^th Jun 2022	Pre-Assessment Letter Sent
Submitted for opposition 88 on 14^th Mar 2022	Security Interest Placed
Submitted for opposition 88 on 25^th Oct 2021	Security Interest Placed
Submitted for opposition 48 on 29^th May 2020	Agent Changed
Submitted for opposition 31 on 27^th Dec 2019	Formalized
Submitted for opposition 1 on 5^th Dec 2019	Created
Submitted for opposition 30 on 4^th Dec 2019	Filed

RUZURGI

Classification Information

Class [005]Pharmaceutical preparations for the treatment of autoimmune, neurological, muscular, and neuromuscular diseases and disorders, namely Lambert-Eaton myasthenic syndrome (LEMS)

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for the treatment of autoimmune, neurological, muscular, and neuromuscular diseases and disorders, namely Lambert-Eaton myasthenic syndrome (LEMS)